Boehringer hopes schizophrenia apps will Click into place

The licensing of digital therapeutics – essentially apps to help people with chronic diseases manage their conditions – has a chequered history, with Sandoz returning the rights to two of Pear Therapeutics’ programmes a year ago. Hoping to defy the odds is Click Therapeutics, which is collaborating with Boehringer Ingelheim on a schizophrenia project in a deal worth up to $500m.